Drug Profile
OncoRad
Latest Information Update: 25 Jun 2008
Price :
$50
*
At a glance
- Originator Cytogen Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 03 Nov 2000 No-Development-Reported for Bladder cancer in USA (Unknown route)
- 03 Nov 2000 No-Development-Reported for Ovarian cancer in USA (Unknown route)
- 03 Nov 2000 No-Development-Reported for Prostate cancer in USA (Unknown route)